miRNA Biomarker Discovery for Early Detection of Breast Cancer

miRNA Biomarker Discovery for Early Detection of Breast Cancer

Invitation to tender

Karolinska Institutet, hereinafter called KI, invites companies and core-facilities, hereinafter called the Tenderers, to submit tenders concerning miRNA Biomarker Discovery for Early Detection of Breast Cancer.

Signed agreement is to be used by the Department of Medical Epidemiology and Biostatistics (MEB) on KI.

miRNA Biomarker Discovery for Early Detection of Breast Cancer

Invitation to tender

Karolinska Institutet, hereinafter called KI, invites companies and core-facilities, hereinafter called the Tenderers, to submit tenders concerning miRNA Biomarker Discovery for Early Detection of Breast Cancer.

Signed agreement is to be used by the Department of Medical Epidemiology and Biostatistics (MEB) on KI.

Agreement term

KI has intention to sign a contract with one (1) supplier.

The agreement shall become effective when the parties, KI and the chosen supplier, have signed the contract.

The agreement shall be valid for two (2) years after both parties have signed. KI has the right to extend the contract one (1) times of two (2) years for a maximum contract period of four (4) years. Provided that the entire purchase must be completed and delivered. KI decides unilaterally whether an extension should take place.

The exact start date shall be determined upon signing of the agreement.

The maximal estimated budget of 2 000 000 SEK.

Please note that the statistics provided here are an estimation and is not a promised volume. The future demand may fall below the amounts indicated here. KI does not offer any volume guarantee; rather, the Tenderer undertakes to fulfill the actual demand that arises.

Contents

The tender request documentation consists of the following document parts:

1. Invitation to tender2. Administrative rules3. Evaluation and qualification4. Supplier qualification5. Technical requirements6. Commercial terms and conditions7. MTAAdditional information published during the procurement procedure is considered to be part of the procurement documents.The Tenderer is responsible for acquiring all of the procurement documents.

Procurement authority

Karolinska InstitutetReg. no: 202100-2973Visiting address:Nobels väg 6171 77 Stockholm

Reception in Aula Medica is staffed on weekdays 8.00 – 17.00.

Contact person during the procurement process

Any questions are to be asked via TendSign.

Contact person:

Cara JohanssonPurchasing and Procurement unite-mail: Cara.johansson@ki.se

Procurement procedure

The procurement is carried out as an open procedure according to Chapter 6, § 2 of the Swedish Public Procurement Act (2016: 1145) (LOU).

For more information on procurement procedures, see upphandlingsmyndigheten.se/upphandla/om-upphandlingsreglerna/Upphandlingsforfaranden.

Tender’s period of validity

The tender must be valid for 6 months after last tender date.

If necessary, KI may request an extension of the tender validity period, for example, if the procurement process or the contract award decision is appealed in court.

Compensation

KI shall reject all Tenderer’s claims for compensation for the work performed during participation in the procurement process.

Description

KI will acquire miRNA Biomarker Discovery for Early Detection of Breast Cancer.

It is the Tenderer´s responsibility to submit a tender for miRNA Biomarker Discovery for Early Detection of Breast Cancer in accordance with the specifications asked for by KI.

Mercell notice: https://opic.com/id/afaajtcphe